Results of heart transplantation in patients with preexisting malignancies. 1997

M M Koerner, and G Tenderich, and K Minami, and H Mannebach, and H Koertke, and E zu Knyphausen, and A El-Banayosy, and D Baller, and K Kleesiek, and U Gleichmann, and H Meyer, and R Koerfer
Heart Center Northrhine-Westphalia, Ruhr University of Bochum, Bad Oeynhausen, Germany.

Twenty patients with end-stage heart failure and preexisting malignancies underwent heart transplantation at a single center, with a neoplasm-free interval before the procedure of 0 to 240 months. Twelve patients were long-term survivors (2 to 72 months); there were 2 early and 6 late deaths, thus justifying heart transplantation in patients with preexisting malignancies in individual cases.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000075202 Contraindications A condition or factor associated with a recipient that makes the use of a drug, procedure, or physical agent improper or inadvisable. Contraindications may be absolute (life threatening) or relative (higher risk of complications in which benefits may outweigh risks). Contraindications, Physical Agent,Medical Contraindications,Agent Contraindication, Physical,Agent Contraindications, Physical,Contraindication,Contraindication, Medical,Contraindication, Physical Agent,Contraindications, Medical,Medical Contraindication,Physical Agent Contraindication,Physical Agent Contraindications

Related Publications

M M Koerner, and G Tenderich, and K Minami, and H Mannebach, and H Koertke, and E zu Knyphausen, and A El-Banayosy, and D Baller, and K Kleesiek, and U Gleichmann, and H Meyer, and R Koerfer
July 1991, Transplantation,
M M Koerner, and G Tenderich, and K Minami, and H Mannebach, and H Koertke, and E zu Knyphausen, and A El-Banayosy, and D Baller, and K Kleesiek, and U Gleichmann, and H Meyer, and R Koerfer
November 2018, Transplantation proceedings,
M M Koerner, and G Tenderich, and K Minami, and H Mannebach, and H Koertke, and E zu Knyphausen, and A El-Banayosy, and D Baller, and K Kleesiek, and U Gleichmann, and H Meyer, and R Koerfer
May 1995, The American journal of cardiology,
M M Koerner, and G Tenderich, and K Minami, and H Mannebach, and H Koertke, and E zu Knyphausen, and A El-Banayosy, and D Baller, and K Kleesiek, and U Gleichmann, and H Meyer, and R Koerfer
June 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
M M Koerner, and G Tenderich, and K Minami, and H Mannebach, and H Koertke, and E zu Knyphausen, and A El-Banayosy, and D Baller, and K Kleesiek, and U Gleichmann, and H Meyer, and R Koerfer
July 2018, Transplantation,
M M Koerner, and G Tenderich, and K Minami, and H Mannebach, and H Koertke, and E zu Knyphausen, and A El-Banayosy, and D Baller, and K Kleesiek, and U Gleichmann, and H Meyer, and R Koerfer
April 1995, Transplantation proceedings,
M M Koerner, and G Tenderich, and K Minami, and H Mannebach, and H Koertke, and E zu Knyphausen, and A El-Banayosy, and D Baller, and K Kleesiek, and U Gleichmann, and H Meyer, and R Koerfer
June 2019, Journal of the American College of Cardiology,
M M Koerner, and G Tenderich, and K Minami, and H Mannebach, and H Koertke, and E zu Knyphausen, and A El-Banayosy, and D Baller, and K Kleesiek, and U Gleichmann, and H Meyer, and R Koerfer
February 1990, The American journal of cardiology,
M M Koerner, and G Tenderich, and K Minami, and H Mannebach, and H Koertke, and E zu Knyphausen, and A El-Banayosy, and D Baller, and K Kleesiek, and U Gleichmann, and H Meyer, and R Koerfer
January 2015, Drug design, development and therapy,
M M Koerner, and G Tenderich, and K Minami, and H Mannebach, and H Koertke, and E zu Knyphausen, and A El-Banayosy, and D Baller, and K Kleesiek, and U Gleichmann, and H Meyer, and R Koerfer
February 2001, Heart (British Cardiac Society),
Copied contents to your clipboard!